Sofia Paul

3.7k total citations · 1 hit paper
24 papers, 2.7k citations indexed

About

Sofia Paul is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Sofia Paul has authored 24 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 7 papers in Molecular Biology. Recurrent topics in Sofia Paul's work include Estrogen and related hormone effects (6 papers), Lung Cancer Diagnosis and Treatment (6 papers) and Lung Cancer Treatments and Mutations (6 papers). Sofia Paul is often cited by papers focused on Estrogen and related hormone effects (6 papers), Lung Cancer Diagnosis and Treatment (6 papers) and Lung Cancer Treatments and Mutations (6 papers). Sofia Paul collaborates with scholars based in United States, Canada and Switzerland. Sofia Paul's co-authors include Frances A. Shepherd, Nasser H. Hanna, Paul A. Bunn, Lawrence Einhorn, Jose R. Pereira, Thomas Chang Yao Tsao, U. Gatzemeier, Paolo Paoletti, Joachim von Pawel and Shaharyar and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Sofia Paul

23 papers receiving 2.6k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy

2004 1.9k citations Nasser H. Hanna, Frances A. Shepherd et al. Journal of Clinical Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Sofia Paul	1.9k	1.8k	464	386	308	24	2.7k
Suneel Mundle	1.5k 0.8×	560 0.3×	913 2.0×	228 0.6×	307 1.0×	131	3.3k
B. Massidda	848 0.4×	1.6k 0.9×	302 0.7×	507 1.3×	77 0.3×	84	2.3k
Shuanzeng Wei	1.0k 0.5×	504 0.3×	908 2.0×	287 0.7×	379 1.2×	73	2.1k
Yasuhide Miyoshi	1.0k 0.5×	593 0.3×	402 0.9×	126 0.3×	306 1.0×	137	2.0k
D. Amoroso	791 0.4×	2.0k 1.1×	455 1.0×	668 1.7×	101 0.3×	104	2.8k
Consuelo Buttigliero	1.0k 0.5×	692 0.4×	411 0.9×	105 0.3×	212 0.7×	91	1.7k
R. Sylvester	976 0.5×	637 0.3×	214 0.5×	207 0.5×	189 0.6×	54	1.9k
Giorgio Cocconi	769 0.4×	1.4k 0.8×	431 0.9×	223 0.6×	68 0.2×	85	2.2k
Francisco Sapunar	846 0.4×	1.1k 0.6×	414 0.9×	585 1.5×	54 0.2×	33	1.7k
Victoria Villaflor	1.2k 0.6×	1.5k 0.8×	600 1.3×	104 0.3×	160 0.5×	132	2.9k

Countries citing papers authored by Sofia Paul

Since Specialization

Citations

This map shows the geographic impact of Sofia Paul's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sofia Paul with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sofia Paul more than expected).

Fields of papers citing papers by Sofia Paul

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sofia Paul. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sofia Paul. The network helps show where Sofia Paul may publish in the future.

Co-authorship network of co-authors of Sofia Paul

This figure shows the co-authorship network connecting the top 25 collaborators of Sofia Paul. A scholar is included among the top collaborators of Sofia Paul based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sofia Paul. Sofia Paul is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Juric, Dejan, Debra L. Richardson, Babar Bashir, et al.. (2023). Tolerability and preliminary activity of the potent, selective, oral CDK7 inhibitor SY-5609 in combination with fulvestrant in patients with advanced hormone receptor-positive (HR+), HER2- breast cancer (BC).. Journal of Clinical Oncology. 41(16_suppl). 3081–3081. 2 indexed citations

Bashir, Babar, Manish Sharma, Dejan Juric, et al.. (2023). Phase 1/1b study of SY-5609, a selective and potent CDK7 inhibitor, in advanced solid tumors and in 2L/3L pancreatic ductal adenocarcinoma (PDAC) in combination with gemcitabine +/- nab-paclitaxel.. Journal of Clinical Oncology. 41(16_suppl). 3080–3080. 2 indexed citations

Hanna, Nasser H., Frances A. Shepherd, Frank V. Fossella, et al.. (2023). Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy. Journal of Clinical Oncology. 41(15). 2682–2690. 8 indexed citations

Sharma, Manish, Babar Bashir, Dejan Juric, et al.. (2022). Trial in progress: Phase I study of SY-5609, a potent, selective CDK7 inhibitor, with initial expansion in adults with metastatic pancreatic cancer.. Journal of Clinical Oncology. 40(16_suppl). TPS4180–TPS4180. 3 indexed citations

Hultcrantz, Malin, Larry D. Anderson, Faiz Anwer, et al.. (2021). MM-392: Belantamab Mafodotin (Belamaf; GSK2857916) US Expanded Access Program (EAP) for Heavily Pre-Treated Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Characteristics. Clinical Lymphoma Myeloma & Leukemia. 21. S439–S440.

Richardson, Paul G., Swethajit Biswas, Beata Holkova, et al.. (2020). DREAMM-5 platform trial: Belantamab mafodotin in combination with novel agents in patients with relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology. 38(15_suppl). TPS8552–TPS8552. 4 indexed citations

Sharma, Sunil, Joachim Beck, Monica Mita, et al.. (2013). A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors. Investigational New Drugs. 31(4). 974–985. 29 indexed citations

Hu, Jing, Sofia Paul, Joanne Schindler, et al.. (2009). Characteristics of Thrombocytopenia in Patients Treated with Oral Panobinostat (LBH589).. Blood. 114(22). 2740–2740. 5 indexed citations

Woo, Margaret M., Harald Weber, Samit Hirawat, et al.. (2009). Population Pharmacokinetics of Panobinostat (LBH589) in Patients with Advanced Solid Tumors and Hematologic Malignancies Following Intravenous and Oral Administration.. Blood. 114(22). 3780–3780. 2 indexed citations

10.

Jiang, Honghua, James T. Symanowski, Sofia Paul, et al.. (2008). The type I error and power of non‐parametric logrank and Wilcoxon tests with adjustment for covariates—A simulation study. Statistics in Medicine. 27(28). 5850–5860. 17 indexed citations

11.

Pujol, Jean-Louis, Sofia Paul, Nadia Chouaki, et al.. (2007). Survival without Common Toxicity Criteria Grade 3/4 Toxicity for Pemetrexed Compared with Docetaxel in Previously Treated Patients with Advanced Non-small Cell Lung Cancer (NSCLC): A Risk-Benefit Analysis. Journal of Thoracic Oncology. 2(5). 397–401. 47 indexed citations

12.

Weiss, Glen J., Corey J. Langer, Rafael Rosell, et al.. (2006). Elderly Patients Benefit From Second-Line Cytotoxic Chemotherapy: A Subset Analysis of a Randomized Phase III Trial of Pemetrexed Compared With Docetaxel in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 24(27). 4405–4411. 120 indexed citations

13.

Hanna, Nasser H., Frances A. Shepherd, Frank V. Fossella, et al.. (2004). Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy. Journal of Clinical Oncology. 22(9). 1589–1597. 1924 indexed citations breakdown →

14.

Hanna, Nasser H., Sofia Paul, Frank V. Fossella, et al.. (2003). O-5 Multiple regression analysis of prognostic variables for survival from the phase III study of pemetrexed versus docetaxel in non-small-cell lung cancer (NSCLC). Lung Cancer. 41. S5–S6. 5 indexed citations

15.

Mosca, Lori, Elizabeth Barrett‐Connor, Nanette K. Wenger, et al.. (2001). Design and methods of the Raloxifene Use for The Heart (RUTH) study. The American Journal of Cardiology. 88(4). 392–395. 129 indexed citations

16.

Anderson, Pamela W., David A. Cox, Andreas Sashegyi, et al.. (2001). Effects of raloxifene and hormone replacement therapy on markers of serum atherogenicity in healthy postmenopausal women. Maturitas. 39(1). 71–77. 15 indexed citations

17.

Walsh, Brian W., Sofia Paul, Robert A. Wild, et al.. (2000). The Effects of Hormone Replacement Therapy and Raloxifene on C-Reactive Protein and Homocysteine in Healthy Postmenopausal Women: A Randomized, Controlled Trial1. The Journal of Clinical Endocrinology & Metabolism. 85(1). 214–218. 285 indexed citations

18.

Baker, Valerie L., Michael Draper, Sofia Paul, et al.. (1998). Reproductive Endocrine and Endometrial Effects of Raloxifene Hydrochloride, a Selective Estrogen Receptor Modulator, in Women With Regular Menstrual Cycles. Obstetrical & Gynecological Survey. 53(4). 224–226. 3 indexed citations

19.

Baker, Valerie L., Michael Draper, Sofia Paul, et al.. (1998). Reproductive Endocrine and Endometrial Effects of Raloxifene Hydrochloride, a Selective Estrogen Receptor Modulator, in Women with Regular Menstrual Cycles1. The Journal of Clinical Endocrinology & Metabolism. 83(1). 6–13. 86 indexed citations

20.

Glusman, J. E., William J. Huster, & Sofia Paul. (1998). Raloxifene effects on vasomotor and other climacteric symptoms in postmenopausal women. Primary Care Update for OB/GYNS. 5(4). 166–166. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact